Compositions for inhibiting MASP-2 dependent complement activation

Patent metadata

Field	Value
Publication number	US-10047165-B2
Application number	US-201615263876-A
Country	US
Kind code	B2
Filing date	Sep 13, 2016
Priority date	May 4, 2011
Publication date	Aug 14, 2018
Grant date	Aug 14, 2018

Abstract

The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

First claim

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A nucleic acid encoding complementarity determining regions (CDRs) of heavy and light chain variable regions of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the heavy and light chain variable regions comprise the amino acid sequences set forth in SEQ ID NO:20 and SEQ ID NO:24, respectively.

2. A nucleic acid comprising a nucleotide sequence encoding heavy and light chain variable regions of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the heavy and light chain variable regions, comprise the amino acid sequences set forth in SEQ ID NO:20 and SEQ ID NO:24, respectively.

3. An expression vector comprising the nucleic acid according to claim 1 or claim 2 .

4. A cell comprising the expression vector according to claim 3 .

5. A method for producing an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, the method comprising culturing the cell of claim 4 under conditions and for a time sufficient to allow expression by the cell of the antibody, or antigen-binding fragment thereof, encoding by the nucleic acid.

6. The method of claim 5 , further comprising isolating the antibody, or antigen-binding fragment thereof.

7. A cell comprising:
(a) a nucleic acid encoding complementarity determining regions (CDRs) of a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:20; and
(b) a nucleic acid encoding complementarity determining regions (CDRs) of a light chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:24.

8. A method for producing an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, the method comprising culturing the cell of claim 7 under conditions and for a time sufficient to allow expression by the cell of the antibody, or antigen-binding fragment thereof, encoded by the nucleic acid.

9. The method of claim 8 , further comprising isolating the antibody, or antigen-binding fragment thereof.

Assignees

• Omeros Corp

Inventors

• Dudler Thomas
• Gombotz Wayne R
• Parent James Brian
• Tedford Clark E
• Kavlie Anita
• Hagemann Urs Beat
• Reiersen Herald
• Kiprijanov Sergej

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/53

  Hinge · CPC title

• C12N9/6424

  Serine endopeptidases (3.4.21) · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• A61K2039/505

  comprising antibodies · CPC title